As synthetic biology continues to grow, advanced benchtop systems are becoming available to make research and product development easier. Now, Inscripta, a digital genome engineering company, has announced the first commercial shipment of its Onyx platform. The platform is the world’s first fully automated benchtop instrument for genome-scale engineering. Inscripta also announced its Series E funding of $150 million. 

“We see a lot of areas where we think our technology can have a real impact,” says Sri Kosaraju, president and CEO of Inscripta. “We are excited to explore them as we are growing.” 

Full-Scale Genome Engineering

Inscripta’s Onyx benchtop system includes the instruments, software, consumables, and assays needed for full-scale genome engineering. The Crispr-mediated platform enables experimentation within cells, so thousands of edits can be made in one run of the instrument. 

Find out more in the Forbes article.